Ka morao

Thalidomide e ile ea hlahisoa e le sedative, immunomodulatory agent hape e fuputsoa bakeng sa ho phekola matšoao a mefuta e mengata ea kankere. Thalidomide e thibela E3 ubiquitin ligase.,e leng setsi sa CRBN-DDB1-Cul4A.

Tlhaloso

Thalidomide qalong e khothalletsoa e le sedative, inhibits cereblon (CRBN), karolo ea cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, e nang le Kd ea∼250 nM, 'me e na le immunomodulatory, anti-inflammatory le anti-angiogenic kankere.

Ka Vitro

Thalidomide qalong e khothalletsoa hore e be sedative, e na le immunomodulatory, anti-inflammatory le anti-angiogenic cancer properties, le targets cereblon (CRBN), karolo ea cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, e nang le Kd ea∼250 nM[1]. Thalidomide (50μg / mL) e etsa hore mosebetsi oa anti-tumor oa icotinib o be khahlanong le ho ata ha lisele tsa PC9 le A549 ka bobeli, 'me phello ena e amana le apoptosis le ho falla ha lisele. Ho phaella moo, Thalidomide le icotinib li thibela litsela tsa EGFR le VEGF-R2 liseleng tsa PC9 [3].

Thalidomide (100 mg/kg, po) e thibela ho beoa ha collagen, e theola boemo ba polelo ea mRNA.α-SMA le collagen I, mme e fokotsa haholo li-cytokine tsa pro-inflammatory ho litoeba tsa RILF. Thalidomide e fokotsa RILF ka ho hatella ROS le ho theola taolo ea TGF-β/Smad tsela e itšetlehileng ka boemo ba Nrf2[2]. Thalidomide (200 mg/kg, po) e kopantsoeng le icotinib e bonts'a litlamorao tsa synergistic anti-tumor ho litoeba tse hlobotseng tse nang le lisele tsa PC9, ho hatella kholo ea hlahala le ho khothaletsa lefu la hlahala[3].